TSX: AMF
TORONTO, Nov. 27 /CNW/ - Amorfix Life Sciences (TSX: AMF), a company
focused on treatments and diagnostics for brain-wasting diseases, today
announced the discovery of misfolded superoxide dismutase 1 (SOD1) protein in
the brains of people with Alzheimer's Disease. This breakthrough result
suggests that SOD1 is a common link between the two brain-wasting diseases,
Alzheimer's and ALS, also known as Lou Gehrig's Disease. SOD1 has a
"Jekyll-and-Hyde" nature as it normally plays an important protective role in
detoxifying free radicals in the body, but when misfolded can create lethal
oxidative free radicals.
"Amorfix previously reported results from pilot studies showing our
proprietary antibodies and vaccines targeting misfolded SOD1 showed life
extension in a mouse model of ALS. Amorfix will now investigate the use of
these same or similar agents to treat Alzheimer's disease," said Dr. Neil
Cashman, Chief Scientific Officer of Amorfix. "Evidence of free radical
toxicity has been observed in Alzheimer's disease for many years and the
discovery of the presence of misfolded SOD1 strongly suggests this toxicity is
associated with SOD1."
click here for the full story
Tuesday, November 27, 2007
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment